Immunomic Therapeutics has filed a notice of an exempt offering of securities to raise $20,900,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Immunomic Therapeutics is raising up to $20,900,000.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Eric Winzer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.
To learn more about Immunomic Therapeutics, visit http://www.immunomix.com/
Contact:
Eric Winzer, Chief Financial Officer
301-968-3509
https://www.linkedin.com/in/eric-winzer-2bb84436/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.